Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patie...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	S Ahmad, S, Qian, W, Ellis, S, Mason, E, Khattak, M, Gupta, A, Shaw, H, Quinton, A, Kovarikova, J, Thillai, K, Rao, A, Board, R, Nobes, J, Dalgleish, A, Grumett, S, Maraveyas, A, Danson, S, Talbot, T, Harries, M, Marples, M, Plummer, R, Kumar, S, Nathan, P, Middleton, M, Larkin, J, Lorigan, P, Wheater, M, Ottensmeier, C, Corrie, P
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	Lippincott, Williams and Wilkins 2015

Ижил төстэй зүйлс

Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.
-н: Lorigan, P, зэрэг
Хэвлэсэн: (2014)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
-н: Dalle, S, зэрэг
Хэвлэсэн: (2021)

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab
-н: M. Hardy-Werbin, зэрэг
Хэвлэсэн: (2018-02-01)

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
-н: Gupta, A, зэрэг
Хэвлэсэн: (2014)

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
-н: Gupta, A, зэрэг
Хэвлэсэн: (2013)

Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
-н: Dalle, S, зэрэг
Хэвлэсэн: (2019)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
-н: Revicki Dennis A, зэрэг
Хэвлэсэн: (2012-06-01)

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
-н: Max Hardy-Werbin, зэрэг
Хэвлэсэн: (2019-06-01)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
-н: Bart Neyns, зэрэг
Хэвлэсэн: (2022-07-01)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
-н: A. A. Formozo, зэрэг
Хэвлэсэн: (2021-01-01)

Results of combined nivolumab and ipilimumab therapy in patients with cancer
-н: M. A. Lyadova, зэрэг
Хэвлэсэн: (2021-12-01)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
-н: Middleton, M, зэрэг
Хэвлэсэн: (2016)

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
-н: Urbonas, V, зэрэг
Хэвлэсэн: (2018)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
-н: M. N. Khagazheeva, зэрэг
Хэвлэсэн: (2022-06-01)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
-н: Joanne M. Jeter, зэрэг
Хэвлэсэн: (2012-01-01)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
-н: W. J. Mullally, зэрэг
Хэвлэсэн: (2022-04-01)

The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK.
-н: James Larkin, зэрэг
Хэвлэсэн: (2015-01-01)

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
-н: K. Kisielewska, зэрэг
Хэвлэсэн: (2024-01-01)

Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab
-н: Quaovi H Sodji, зэрэг
Хэвлэсэн: (2020-05-01)

Panhypopituitarism induced by ipilimumab
-н: Miyu Shiratori, зэрэг
Хэвлэсэн: (2020-01-01)

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
-н: O'Brien, M, зэрэг
Хэвлэсэн: (2013)

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes
-н: Chen P, зэрэг
Хэвлэсэн: (2018-07-01)

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
-н: Weber, J, зэрэг
Хэвлэсэн: (2019)

Acute visual loss after ipilimumab treatment for metastatic melanoma
-н: Melissa A. Wilson, зэрэг
Хэвлэсэн: (2016-11-01)

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
-н: Ian M. Bouligny, зэрэг
Хэвлэсэн: (2025-02-01)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
-н: Celeste Lebbe, зэрэг
Хэвлэсэн: (2023-05-01)

IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
-н: I. V. SAMOILENKO, зэрэг
Хэвлэсэн: (2016-12-01)

Ipilimumab-Induced Neutropenia in Melanoma
-н: Makiko Ban-Hoefen MD, зэрэг
Хэвлэсэн: (2016-08-01)

Ipilimumab induced digital vasculitis
-н: Amrita Padda, зэрэг
Хэвлэсэн: (2018-02-01)

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
-н: Lipplaa, A, зэрэг
Хэвлэсэн: (2018)

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab
-н: Alexandre Reuben, зэрэг
Хэвлэсэн: (2017-12-01)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
-н: Remon J, зэрэг
Хэвлэсэн: (2019-05-01)

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
-н: Dangoor, A, зэрэг
Хэвлэсэн: (2010)

Ipilimumab and nivolumab in uveal melanoma: report on toxicity and treatment intensity
-н: A. Ciernik, зэрэг
Хэвлэсэн: (2024-01-01)

Engineered ipilimumab variants that bind human and mouse CTLA-4
-н: Brett Robison, зэрэг
Хэвлэсэн: (2025-12-01)

Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas
-н: Santosh Kesari, зэрэг
Хэвлэсэн: (2024-12-01)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
-н: Serigne Lo, зэрэг
Хэвлэсэн: (2020-10-01)

Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
-н: Margot Stagnetto, зэрэг
Хэвлэсэн: (2020-11-01)

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
-н: Edward Cha, зэрэг
Хэвлэсэн: (2013-04-01)

Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.
-н: Sabharwal, A, зэрэг
Хэвлэсэн: (2011)